Companies: 48,874 Total Market Cap: 131167492431003.07

Lavipharm S.A.

ATH-LAVI

Healthcare Drug Manufacturers - Specialty & Generic

Rank #21186

Market Cap 153.45 M

Volume 99,972.38

Price 0.91

Change (%) 0.73%

Country or region

Greece

Lavipharm S.A.'s latest marketcap:

153.45 M

As of May 14, 2025, Lavipharm S.A.'s market capitalization has reached $153.45 M. According to our data, Lavipharm S.A. is the 21186th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap	153.45 M
Revenue (ttm)	59.24 M
Net Income (ttm)	10.05 M
Shares Out	168.69 M
EPS (ttm)	0.06
Forward PE	0.00
Ex-Dividend Date	n/a
Earnings Date	May 12, 2025

Market Cap Chart

Data Updated: May 14, 2025

Lavipharm S.A.'s yearly market capitalization.

Lavipharm S.A. has seen its market value grow from €24.01 M to €137.15 M since 2020, representing a total increase of 471.25% and an annual compound growth rate (CAGR) of 49.03%.

Date	Market Cap	Change (%)
May 14, 2025	€137.15 M	2.26%
December 31, 2024	€134.11 M	0.36%
December 29, 2023	€133.62 M	107.29%
December 30, 2022	€64.46 M	117.58%
December 31, 2021	€29.63 M	23.4%
December 31, 2020	€24.01 M

Company Profile

About Lavipharm S.A.

Lavipharm S.A. is a leading pharmaceutical company specializing in the research, development, manufacturing, and distribution of healthcare products. Established in 1911, the company is headquartered in Paiania, Greece, and serves both domestic and international markets.

Core Business Activities

Research and development of pharmaceutical and dermocosmetic products
Manufacturing, import, and wholesale distribution
Marketing and sales to physicians and pharmacists

Product Portfolio

Lavipharm offers a diverse range of healthcare solutions, including:

Pharmaceutical products for cardiology, oncology-urology, central nervous system, and chronic pain management
Self-treatment solutions
Prescription medicines and over-the-counter (OTC) products
LIFELAB CBD line of products

Frequently Asked Questions

As of May 14, 2025, Lavipharm S.A. (including the parent company, if applicable) has an estimated market capitalization of $153.45 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Lavipharm S.A. global market capitalization ranking is approximately 21186 as of May 14, 2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region	Greece
Founded	1911
IPO Date	n/a
Employees	299
CEO	Telemaque Lavidas
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Address	12, Agias Marinas Street Paiania, 190 02 Greece